Marvel Biosciences Corp (TSE:MRVL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Marvel Biosciences Corp. has announced that its drug MB204 shows promising preclinical results, outperforming the approved drug Trofinetide in treating Rett syndrome. The study highlighted MB204’s ability to improve social behaviors and cognition with a lower dosage and longer-lasting effects, indicating a potential breakthrough in therapy.
For further insights into TSE:MRVL stock, check out TipRanks’ Stock Analysis page.